1. Evaluation of Left Ventricular Enlargement as a Marker of Early Disease in Familial Dilated CardiomyopathyClinical Perspective
by Diane Fatkin, Thomas Yeoh, Christopher S. Hayward, Victoria Benson, Angela Sheu, Zara Richmond, Michael P. Feneley, Anne M. Keogh, and Peter S. Macdonald
Circ Genom Precis Med
Volume 4(4):
August 16, 2011
Copyright © American Heart Association, Inc. All rights reserved.

2. Results of baseline screening and follow-up of asymptomatic relatives of patients with familial dilated cardiomyopathy (DCM). dFS indicates depressed left ventricular (LV) fractional shortening; and LVE, LV enlargement. *The outcomes of relatives with LVE (n=72) who were not receiving any treatment during the period between progress echocardiograms (“natural history” cohort) are indicated by the black lines.
Results of baseline screening and follow-up of asymptomatic relatives of patients with familial dilated cardiomyopathy (DCM). dFS indicates depressed left ventricular (LV) fractional shortening; and LVE, LV enlargement. *The outcomes of relatives with LVE (n=72) who were not receiving any treatment during the period between progress echocardiograms (“natural history” cohort) are indicated by the black lines. Six of these individuals subsequently crossed over to the treatment group and underwent further follow-up. †Cardiovascular medications, including β-blockers, angiotensin-converting enzyme inhibitors, and calcium antagonists, were administered for various indications (DCM prophylaxis, hypertension, palpitations, atrial fibrillation) at some time during the follow-up period.
Diane Fatkin et al. Circ Cardiovasc Genet. 2011;4:
Copyright © American Heart Association, Inc. All rights reserved.

3. Receiver operating characteristic analysis of different methods for assessment of left ventricular (LV) dilation in asymptomatic relatives and healthy control subjects.
Receiver operating characteristic analysis of different methods for assessment of left ventricular (LV) dilation in asymptomatic relatives and healthy control subjects. AUC indicates area under the curve; Framingham, criteria based on data from the Framingham Heart Study; LV end-diastolic diameter (LVEDD) differences from 95th percentile values are shown; NHLBI indicates criteria formulated by the National Heart, Lung, and Blood Institute expert panel; and LVEDD (% predicted), ratio of actual LVEDD to predicted diameter, expressed as a percentage.
Diane Fatkin et al. Circ Cardiovasc Genet. 2011;4:
Copyright © American Heart Association, Inc. All rights reserved.